Mg 5-Sulfat Amp. Drossapharm (Magnesium Sulfate Heptahydrate)

Magnesium sulfate supplies Mg2+ ions that serve as cofactors for many enzymatic reactions, stabilise cell membranes, antagonise calcium entry, and modulate voltage‑gated ion channels. These actions help normalise neuromuscular transmission, vascular tone, and cardiac electrophysiology, thereby correcting magnesium deficiency.

The appropriate dose of magnesium sulfate is determined by the prescribing clinician based on the patient’s clinical condition, serum magnesium level, and therapeutic goal. Dosing regimens vary widely, so the prescriber sets the exact amount and infusion rate.

Magnesium sulfate is commonly used in obstetrics for seizure prophylaxis in pre‑eclampsia and eclampsia, and its safety profile in pregnancy is well established. However, the product’s specific pregnancy category is listed as unknown, and clinicians should weigh benefits against any potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Magnesium sulfate uniquely provides magnesium ions, which are essential for over 300 enzymatic processes and for stabilising cardiac and neuromuscular function. Unlike sodium or potassium salts, it specifically corrects magnesium deficiency and has a direct role in preventing seizures in pre‑eclampsia, making it the preferred choice when magnesium repletion is required.

The ampoules should be stored at ambient temperature, away from direct sunlight and moisture. Keep them in the original packaging until use, and avoid exposing them to extreme temperatures or physical shock that could compromise the glass container.

Mg 5‑Sulfat Amp. Drossapharm is administered intravenously. The ampoule is added to a compatible IV fluid or given as a direct IV push, following the prescriber’s instructions regarding infusion rate, concentration and monitoring parameters.

Serious adverse events include respiratory depression, severe hypotension, cardiac arrest, hypermagnesemia‑induced arrhythmias, profound muscle weakness and anaphylactic reactions. Continuous monitoring of vital signs and serum magnesium levels is essential during infusion, especially in patients with renal or cardiac impairment.

Magnesium sulfate is contraindicated in patients with known hypersensitivity to magnesium salts, severe renal failure where clearance is impaired, and in those with existing severe heart block or profound hypotension unless under close medical supervision.